Valuation: Phytopharm plc

Market Cap 27.92M 36.92M 33.46M 30.94M 52.61M 3.48B 54.47M 372M 147M 1.86B 139M 136M 5.9B P/E 2026 *
-9.11x
P/E 2027 * -9.81x
Enterprise Value 17.72M 23.43M 21.23M 19.64M 33.39M 2.21B 34.57M 236M 93.55M 1.18B 87.93M 86.06M 3.75B EV / Sales 2026 *
2.21x
EV / Sales 2027 * 2.42x
Free-Float
89.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-2.69%-0.48%+53.97%+66.82% 66.33B
-0.92%+7.67%+12.64%+93.22% 60.62B
0.00%+0.39%+22.34%+89.58% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
-2.32%-2.24%+76.50%+56.02% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.61%+0.05%+36.79%+176.56% 45B
Weighted average by Cap. -0.83%+0.20%+36.63%+152.23%

Financials

2026 *2027 *
Net sales 8M 10.58M 9.59M 8.87M 15.08M 997M 15.61M 107M 42.23M 533M 39.7M 38.86M 1.69B 9M 11.9M 10.78M 9.98M 16.96M 1.12B 17.56M 120M 47.51M 599M 44.66M 43.71M 1.9B
Net income -2.1M -2.78M -2.52M -2.33M -3.96M -262M -4.1M -27.96M -11.09M -140M -10.42M -10.2M -444M -2.8M -3.7M -3.36M -3.1M -5.28M -349M -5.46M -37.28M -14.78M -186M -13.89M -13.6M -592M
Net Debt -10.2M -13.49M -12.22M -11.31M -19.22M -1.27B -19.9M -136M -53.85M -679M -50.61M -49.54M -2.16B -6.1M -8.07M -7.31M -6.76M -11.5M -761M -11.9M -81.22M -32.2M -406M -30.27M -29.63M -1.29B
Logo Phytopharm plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Phytopharm plc